Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases
May 15, 2024 16:01 ET
|
Apogee Therapeutics, LLC
Interim clinical data from APG777 Phase 1 healthy volunteers study exceeded all trial objectives and achieved a half-life of approximately 75 days with a potentially best-in-class profile 16-week...
Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results
May 13, 2024 07:00 ET
|
Apogee Therapeutics, LLC
Initiated a Phase 2 clinical trial of APG777, a subcutaneous half-life extended monoclonal antibody targeting IL-13, in patients with moderate-to-severe atopic dermatitis, with 16-week...
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Rα Antibody for the Treatment of Chronic Obstructive Pulmonary Disease (COPD) and Other Inflammatory Diseases
March 25, 2024 07:00 ET
|
Apogee Therapeutics, LLC
Preclinical data with APG808 demonstrate the potential for improved dosing over other treatment options in development, including the potential for dosing every six- or eight- weeks compared to dosing...
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $483 Million
March 12, 2024 16:01 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO, Calif. and WALTHAM, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated...
Apogee Therapeutics, Inc. Announces Pricing of Upsized $420 Million Underwritten Public Offering
March 07, 2024 18:49 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 07, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
March 05, 2024 16:23 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company seeking to develop differentiated biologics for...
Apogee Therapeutics Provides Pipeline Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
March 05, 2024 06:10 ET
|
Apogee Therapeutics, LLC
Positive interim results from APG777 Phase 1 healthy volunteer clinical trial exceeded objectives with approximately 75-day half-life which supports the potential for higher exposures leading to...
Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Schedule with Half-Life of Approximately 75 Days
March 05, 2024 06:00 ET
|
Apogee Therapeutics, LLC
Pharmacokinetic data support potential best-in-class profile with potential for improved clinical responses from greater exposures in induction than currently available biologic therapies and...
Apogee to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases on March 5, 2024
March 04, 2024 16:01 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...
Apogee Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024 07:30 ET
|
Apogee Therapeutics, LLC
SAN FRANCISCO and WALTHAM, Mass., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing differentiated biologics for the...